Skip to content
Screener

MapLight Therapeutics, Inc. MPLT Debt-to-equity

Debt-to-equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.9×-0.9×
Johnson & Johnson logo
Johnson & JohnsonJNJ
0.6×-0.1×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
0.1×-0.1×
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
0.1×0.0×
AbbVie logo
AbbVieABBV
46.6×+38.6×
LBR
LB Pharmaceuticals IncLBRX
0×—

Other financials

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M—
Total debt$5.6M—
Total equity$399.8M+285%
Total assets$418.8M—

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K—
Free cash flow-$51.2M—

Valuation

See full
Market cap$602.19M-13.2%
Enterprise value$552.07M—

Returns & leverage

See full
Return on equity-216.8%—
Current ratio22.9×—

Where this comes from

Calculated from MapLight Therapeutics, Inc.’s reported figures.

total debt/total stockholders equity=0×

Based on the most recent quarter.

The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 4:25 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-224129

FAQ

What is MapLight Therapeutics, Inc.'s debt-to-equity?
MapLight Therapeutics, Inc. (MPLT) reported debt-to-equity of 0× in Q1 2026.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about MapLight Therapeutics, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude